Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • S101: OMISSION OF RADIOTHERAPY...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)

Bibliographic Details
Published in:HemaSphere
Main Authors: Maurizio Martelli, Luca Ceriani, Emanuele Zucca, Irina Kryachok, Giovannino Ciccone, Umberto Ricardi, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Sara Veronica Usai, Elsa Pennese, Luca Arcaini, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Francesco Marli, Weili Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Francesco Zaja, Attilio Guarini, Michele Spina, Alexander Fossa, Kate Cwynarski, N. George Mikhaeel, Mats Jerkeman, Andrea Janíková, Andreas Huettmann, Maria Gomes Da Silva, Don Stevens, Luigi Petrucci, Sally Barrington, Bogdan Malkowski, Ur Metser, Annibale Versari, Oreste Bagni, Stephane Chauvie, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Franco Cavalli, Mary Gosodarowicz, Peter W. Johnson, Andrew Davies
Format: Article
Language:English
Published: Wiley 2023-08-01
Online Access:http://journals.lww.com/10.1097/01.HS9.0000967312.24545.68
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000967312.24545.68

Similar Items

  • IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
    by: Anastasios Stathis, et al.
    Published: (2024-02-01)
  • IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
    by: Maria Cristina Pirosa, et al.
    Published: (2022-12-01)
  • Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
    by: Emilio Iannitto, et al.
    Published: (2024-03-01)
  • <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
    by: Emilio Iannitto, et al.
    Published: (2025-04-01)
  • The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study
    by: Davide Rossi, et al.
    Published: (2015-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs